Recall: Quinapril-Hctz
Nov. 2022Pharmacy Updates
Aurobindo Pharma USA Inc. has recalled two lots of quinapril and hydrochlorothiazide tablets due to detection of a nitrosamine (N-nitrosoquinapril) impurity in amounts above the Acceptable Daily Intake level. Nitrosamines may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time. Read the full text of the Quinapril-Hctz recall.
Recent Announcements
Asymptomatic Severe Coronary Disease: Detection to Decisions. Do We Know The Proper Management?
In this new CME course, Krishna V. Tummalapalli, MD, interventional cardiologist, UPMC Heart and Vascular Institute, discusses how to explain the importance of early detection of coronary artery disease, as well as how to describe how early identification can reduce future cardiovascular events and identify appropriate first line medical therapy strategies for patients with asymptomatic stable ischemic heart disease.Mar. 2026Education/Webinars
CME Webinar Series: Introducing Physicians and their teams to Value-Based Health Care
Please join us for a new CME-accredited webinar series on value-based care. This series is designed to introduce practicing physicians and their teams to value-based health care. Over the course of six sessions, we will define the components of value and identify the tools necessary to deliver high-value care for a population.Feb. 2026Education/Webinars